Cargando…

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

Chimeric antigen receptor-T (CAR-T) cells and antibody-drug conjugates (ADCs) are promising therapeutic strategies in oncology. The carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is overexpressed in tumors including non-small cell lung cancer (NSCLC) and pancreatic ductal adenoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ye-Jin, Li, Wei, Zhelev, Doncho V., Mellors, John W., Dimitrov, Dimiter S., Baek, Du-San
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010383/ https://www.ncbi.nlm.nih.gov/pubmed/36923424 http://dx.doi.org/10.3389/fonc.2023.1124039

Ejemplares similares

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody
por: Liu, Xianglei, et al.
Publicado: (2021)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope
por: Raman, Swetha, et al.
Publicado: (2021)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Human antibody V(H) domains targeting uPAR as candidate therapeutics for cancers
por: Chu, Xiaojie, et al.
Publicado: (2023)

Editorial: Therapeutic antibody domains against cancer
por: Zhao, Qi, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6
por: Chan, C.H.F., et al.
Publicado: (2007)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
por: Pascual-Pasto, Guillem, et al.
Publicado: (2022)

Conjugates of Small Molecule Drugs with Antibodies and Other Proteins
por: Feng, Yang, et al.
Publicado: (2014)

Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases
por: Chu, Xiaojie, et al.
Publicado: (2021)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells
por: Phanthaphol, Nattaporn, et al.
Publicado: (2021)

Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 Promotes Carcinogenesis of Gastric Cancer and Anti-CEACAM6 Fluorescent Probe Can Diagnose the Precancerous Lesions
por: An, Fangmei, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy
por: Lipe, Demis N., et al.
Publicado: (2023)

T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction
por: Pinkert, Jessica, et al.
Publicado: (2021)

CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
por: Ye, Mingyu, et al.
Publicado: (2022)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis
por: Jang, Jong Keon, et al.
Publicado: (2022)

Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis
por: Chen, Li-Rong, et al.
Publicado: (2022)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma
por: Löffek, Stefanie, et al.
Publicado: (2015)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy
por: Wang, Yang, et al.
Publicado: (2022)

Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series
por: Dhaliwal, Armaan, et al.
Publicado: (2023)

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
por: Sun, Zehua, et al.
Publicado: (2023)

A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma
por: Rather, Gulam M., et al.
Publicado: (2019)

Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
por: Yan, Nan, et al.
Publicado: (2021)

Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey
por: Ghafoor, Saad, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
por: Marzal-Alfaro, María Belen, et al.
Publicado: (2021)

Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism?
por: Marcucci, Fabrizio, et al.
Publicado: (2019)

Novel chimeric antigen receptor T cells based on T-cell receptor-like antibodies
por: Zhao, Qi
Publicado: (2019)

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hs20tenp09i4gt7185chnu7o6s